Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · IEX Real-Time Price · USD
7.61
-0.26 (-3.30%)
At close: Jul 19, 2024, 4:00 PM
7.74
+0.13 (1.71%)
Pre-market: Jul 22, 2024, 7:36 AM EDT
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $46.24M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $13.79M with 13.68% year-over-year growth. In the year 2023, Recursion Pharmaceuticals had annual revenue of $44.58M with 11.88% growth.
Revenue (ttm)
$46.24M
Revenue Growth
-0.88%
P/S Ratio
42.97
Revenue / Employee
$92,470
Employees
500
Market Cap
1.99B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
Dec 31, 2019 | 2.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 9.37B |
Novavax | 996.61M |
Amphastar Pharmaceuticals | 676.21M |
10x Genomics | 625.45M |
NovoCure | 525.66M |
Catalyst Pharmaceuticals | 411.35M |
Immunocore Holdings | 264.25M |
Arvinas | 71.30M |
RXRX News
- 25 days ago - Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock - GlobeNewsWire
- 25 days ago - Recursion Announces Proposed Offering of Class A Common Stock - GlobeNewsWire
- 27 days ago - Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data - Business Wire
- 27 days ago - Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day - GlobeNewsWire
- 6 weeks ago - Nvidia Owns These 4 Stocks. Here's How They're Doing. - Barrons
- 7 weeks ago - Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool - GlobeNewsWire
- 2 months ago - Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board - GlobeNewsWire
- 2 months ago - Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry - GlobeNewsWire